An observational study in Acute Kidney Injury, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University of Nottingham · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Acute Kidney Injury with a site in United Kingdom — 16 open to participants now, 21 under way, none of them phase 3. Acute Kidney Injury · United Kingdom.
Among the 77 studies in Acute Kidney Injury with a site in United Kingdom, this one is the 29th largest by planned enrollment of the 46 observational ones that give a count, is one of 7 that started in 2026, is one of 46 observational ones, reaches primary completion later than 18 of the 20 other live ones, and was the 73rd registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →16 of the 77 studies in Acute Kidney Injury with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Argentina and 11 more countries
Ages 18–80
CSL Behring · Sites in United Kingdom, United States, Turkey
Ages 12+
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Bayer · Sites in United Kingdom, Germany
Ages 18+
University of Alberta · Sites in United Kingdom, United States, Canada
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 100 across the 31 interventional studies, 243 across the 46 observational. Of the 48 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 77 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 4 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Kidney Injury with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT06446739University of AlbertaLoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM) | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07447791Guy's and St Thomas' NHS Foundation TrustWISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients | 2027-01-31 |
| NCT06772025BayerA Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine | 2027-01-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 77 studies in Acute Kidney Injury with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are:
Participants will be asked to do one or more of:
Observational study workstream: secondary care nephrology clinics Qualitative interview workstream: secondary care nephrology clinics, hospitalised patients with AKI not followed up in nephrology clinic, participants of other aspects of the study.
Participatory workshop workstream: Organisational and professional organisations with interest in acute kidney injury, professional networks, public and patient involvement and engagement groups
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Observational study workstream
Exclusion Criteria:
Observational study workstream
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients 3 months after hospitalised acute kidney injury
Diagnostic Test: Iohexol renal clearance measurement · Diagnostic Test: Cystatin C · Diagnostic Test: Creatinine · Diagnostic Test: Metagenome analysis · Diagnostic Test: Bioimpedance analysis · Other: Patient reported outcome measures · Other: Measurement of physical performance
Patients 3 months after hospitalised acute kidney injury
Other: Semi structured interview
Individuals with personal or professional experience of acute kidney injury
Other: Participatory workshop
Gold standard measurement of glomerular filtration rate.
Estimated GFR using serum cystatin C
eGFR from serum creatinine level
Semi structured interview to explore patient experiences. Purposive sampling will be used to explore a wide range of perspectives and transcripts will be analysed using thematic analysis to develop codes and themes.
Group workshop using qualitative methods. Purposive sampling will be used to explore a wide range of perspectives and transcripts will be analysed using thematic analysis to develop codes and themes. These will be used to develop consensus recommendations.
Analysis of the metagenome using faecal samples of participants after acute kidney injury
Estimation of body composition
EQ-5D-5L, KSQ, WHO-DAS 2.0, K10
Hand grip, Short physical performance battery
The proportion of eligible patients who agree to participate
Time frame: 3 months
The proportion of participants who have all three measurements (eGFR-cystatin, eGFR-creatinine and measured GFR)
Time frame: 3 months
Standard deviation of the difference between measured GFR and eGFR-creatinine and eGFR-cystatin
Time frame: 3 months
The proportion of patients with eGFR <60ml/min/1.73m2 from eGFR-cystatin compared with eGFR creatinine
Time frame: 3 months
Gut microbiome composition
Assessed through metagenomics
Time frame: 3 months
Codes and themes related to patient experience after AKI, identified from systematic qualitative analysis of interview transcripts
Time frame: 3 - 12 months
Production of a document of recommended next steps through MDT development during participatory workshops
Time frame: At completion of third workshop 3 years after enrolment
The mean difference between eGFR-cystatin and eGFR-creatinine
Time frame: 3 months
The mean difference between iohexol measured GFR and each estimated GFR method (creatinine and cystatin)
Time frame: 3 months
Correlation between eGFR creatinine and eGFR cystatin
Time frame: 3 months
Correlation between iohexol measured GFR and each estimated GFR method (creatinine and cystatin)
Time frame: 3 months
Bias between iohexol measured GFR and each estimated GFR method (creatinine and cystatin)
Time frame: 3 months
Accuracy of eGFR creatinine and eGFR cystatin compared with iohexol measured GFR as assessed by the percentage of estimated values within 30% of measured GFR (P30)
Time frame: 3 months
Correlation of muscle mass with the percentage difference between eGFR-cystatin and eGFR-creatinine
Time frame: 3 months
Correlation of physical function with the percentage difference between eGFR-cystatin and eGFR-creatinine
Time frame: 3 months
Correlation of patient reported outcomes with the percentage difference between eGFR-cystatin and eGFR-creatinine
Time frame: 3 months
Barriers to implementation of recommendations as identified through MDT discussion at participatory workshops
Time frame: At completion of third workshop 3 years after enrolment
Safety Outcomes
* Adverse events spontaneously reported during the study * Discontinuation due to adverse events
Time frame: From enrolment until the end of study visits (from 3 to 12 months)
Plan to share: Undecided — IPD sharing will be available on request through the study team and individual applications will be considered.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 23 months is close to that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.